SARASOTA, Fla., March 5, 2013 /PRNewswire/ -- The Sarasota, Florida based Diagnostic Center for Disease™ in conjunction with PanAm HIFU, LLC, released data today showing a 95% cure rate with HIFU (High Intensity Focused Ultrasound) in more than 200 patients at more than 7 years post treatment. This group of patients had biopsy proven prostate cancer in conjunction with a 3.0 Tesla Magnetic Resonance Imaging Spectroscopy scan (MRI-S). Ronald E. Wheeler, M.D. (Medical Director) attributes the results to excellence in imaging, excellence in application of technology as well as excellence in patient selection. While MRI-S continues to be evaluated in a head to head comparison to random prostate biopsies, it appears the MRI-S scan is the missing piece of the diagnostic puzzle allowing for a dramatic improvement in treatment results. Approximately 700,000 American men receive a negative prostate biopsy result; however approximately 25% of these results are false-negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man's prostate. This approach leaves men at risk for a hidden cancer, leading to a high rate of repeat biopsies, often on cancer-free men, which hinders or delays the application of a procedure with this high rate of cure.
Specifically, the MRI-S scan allows for an enhancement of various diagnostic discrimination factors including: evidence of extracapsular extension (ECE), dominance of cancer in a side to side assessment, true density of tissue based on a diffusion weighted image sequence (DWI), dynamic contrast enhancement (DCE) and spectroscopy (if assessable). Once the patient assessment has taken place, a qualified HIFU treating expert can expect to experience predictably better results than those achieved without the MRI-S scan. Dr. Wheeler goes on to say that current worldwide data with HIFU (regardless of technology utilized) supports a cure rate of approximately 78-80%. Our data is a seminal study that enables prostate cancer patients the opportunity to improve their choice of one therapy versus another.
PanAm HIFU Comments:
This press release speaks to the importance of patient selection prior to the HIFU treatment decision. HIFU is not a one-size-fits-all treatment; patients must be appropriate candidates for HIFU. Pre-treatment evaluation including Multi-Parametric MRI, is Dr. Wheeler’s preferred approach to patient selection. Through his experience treating patients with HIFU for more than 7 years, Dr. Wheeler strives to continually advance his techniques; the result – a high rate of success.